DK1079826T3 - Anvendelse af indigoide bisindolderivater til fremstilling af et medikament til inhibering af cyclinafhængige kinaser - Google Patents

Anvendelse af indigoide bisindolderivater til fremstilling af et medikament til inhibering af cyclinafhængige kinaser

Info

Publication number
DK1079826T3
DK1079826T3 DK99926420T DK99926420T DK1079826T3 DK 1079826 T3 DK1079826 T3 DK 1079826T3 DK 99926420 T DK99926420 T DK 99926420T DK 99926420 T DK99926420 T DK 99926420T DK 1079826 T3 DK1079826 T3 DK 1079826T3
Authority
DK
Denmark
Prior art keywords
indigoidal
cyclin
inhibition
drug
preparation
Prior art date
Application number
DK99926420T
Other languages
English (en)
Inventor
Gerhard Eisenbrand
Doris Marko
Weici Tang
Laurent Meijer
Ralph Hoessl
Original Assignee
Centre Nat Rech Scient
Eisenbrand Gerhard Prof Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98109845A external-priority patent/EP0966963A1/en
Application filed by Centre Nat Rech Scient, Eisenbrand Gerhard Prof Dr filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of DK1079826T3 publication Critical patent/DK1079826T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK99926420T 1998-05-29 1999-05-26 Anvendelse af indigoide bisindolderivater til fremstilling af et medikament til inhibering af cyclinafhængige kinaser DK1079826T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98109845A EP0966963A1 (en) 1998-05-29 1998-05-29 Use of indigoid bisindole derivatives as CDK1 inhibitors
EP99105693 1999-03-19
PCT/EP1999/003625 WO1999062503A2 (en) 1998-05-29 1999-05-26 Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases

Publications (1)

Publication Number Publication Date
DK1079826T3 true DK1079826T3 (da) 2003-06-23

Family

ID=26149292

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99926420T DK1079826T3 (da) 1998-05-29 1999-05-26 Anvendelse af indigoide bisindolderivater til fremstilling af et medikament til inhibering af cyclinafhængige kinaser

Country Status (14)

Country Link
EP (1) EP1079826B1 (da)
JP (1) JP2002516851A (da)
KR (1) KR20010078722A (da)
AT (1) ATE233560T1 (da)
AU (1) AU762830B2 (da)
BR (1) BR9910810A (da)
CA (1) CA2333661A1 (da)
DE (1) DE69905712T2 (da)
DK (1) DK1079826T3 (da)
ES (1) ES2194468T3 (da)
HU (1) HUP0102240A3 (da)
IL (1) IL139914A0 (da)
NO (1) NO20006027L (da)
WO (1) WO1999062503A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
GB9904933D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
HUP0200724A3 (en) * 1999-04-12 2002-10-28 Eisenbrand Gerhard Indigoid bisindole derivatives and pharmaceurical compositions containing them
ATE427746T1 (de) * 1999-04-12 2009-04-15 Heinz Herbert Fiebig 5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren
WO2002030410A2 (en) * 2000-10-10 2002-04-18 Board Of Regents, The University Of Texas System Suppression of cyclin kinase activity for prevention and treatment of infections
DE10053474A1 (de) * 2000-10-24 2002-05-02 Schering Ag Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
DE10061162A1 (de) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung
AU2002246659A1 (en) * 2000-12-18 2002-08-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds
FR2821358B1 (fr) * 2001-02-27 2006-04-07 Aventis Pharma Sa Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique
DE10114138C2 (de) * 2001-03-16 2003-03-27 Schering Ag Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit
DE10125763A1 (de) * 2001-05-17 2002-11-28 Schering Ag Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren
DE10129028A1 (de) * 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
US6566341B1 (en) * 2001-12-13 2003-05-20 Natrogen Therapeutics, Inc. Derivative of isoindigo, indigo and indirubin for the treatment of cancer
US7582670B2 (en) 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
EP1458734B1 (en) * 2001-12-13 2010-10-13 Natrogen Therapeutics, Inc. Derivatives of isoindigo, indigo and indirubin and use in treating cancer
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
CN100564375C (zh) * 2002-04-03 2009-12-02 阿勒根公司 作为激酶抑制剂的(3z)-3-(2,3-二氢-1h-茚-1-叉)-1,3-二氢-2h-吲哚-2-酮
CN1199946C (zh) * 2002-10-29 2005-05-04 无锡杰西医药科技有限公司 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
EA012602B1 (ru) * 2004-05-12 2009-10-30 Байер Кропсайенс Аг Регулирование роста растений
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
CN1329376C (zh) * 2005-09-19 2007-08-01 无锡杰西医药科技有限公司 一种n(1)-烃基-3′-肟基靛玉红衍生物(i)的制备方法及其医学应用
JP4587961B2 (ja) * 2006-01-16 2010-11-24 独立行政法人科学技術振興機構 神経因性疼痛治療剤
EP2199292A1 (en) 2008-12-22 2010-06-23 Technische Universität Kaiserlautern 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
EP2379549B1 (en) 2008-12-22 2016-09-21 Eisenbrand, Gerhard 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament
FR2945747A1 (fr) 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
FR2952818B1 (fr) * 2009-11-23 2013-05-31 Oreal Composition contenant au moins un precurseur de coloration derive d'indole, au moins un colorant indoline dione et au moins un compose organique liquide
KR101180030B1 (ko) * 2010-02-05 2012-09-05 광주과학기술원 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체
US8524121B2 (en) * 2012-01-27 2013-09-03 Xerox Corporation Bi-indoline-dithione polymers
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103333161B (zh) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
CN113773243B (zh) * 2021-09-01 2023-01-06 大连理工大学 一种有机催化氧化吲哚自缩合制备异靛蓝类化合物的方法
AU2022360542A1 (en) 2021-10-08 2024-04-18 Azora Therapeutics, Inc. Derivatives of aryl hydrocarbon receptor agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617254A (ja) * 1984-06-20 1986-01-13 Isukura Sangyo Kk ビスインドリノンおよびそれを主成分とする制癌剤
AU4155697A (en) * 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Also Published As

Publication number Publication date
JP2002516851A (ja) 2002-06-11
NO20006027D0 (no) 2000-11-28
WO1999062503A2 (en) 1999-12-09
EP1079826A2 (en) 2001-03-07
HUP0102240A2 (hu) 2001-11-28
KR20010078722A (ko) 2001-08-21
HUP0102240A3 (en) 2003-05-28
WO1999062503A3 (en) 2000-01-27
NO20006027L (no) 2001-01-22
ES2194468T3 (es) 2003-11-16
IL139914A0 (en) 2002-02-10
BR9910810A (pt) 2001-02-13
CA2333661A1 (en) 1999-12-09
AU762830B2 (en) 2003-07-03
EP1079826B1 (en) 2003-03-05
DE69905712T2 (de) 2004-01-29
ATE233560T1 (de) 2003-03-15
DE69905712D1 (de) 2003-04-10
AU4368799A (en) 1999-12-20

Similar Documents

Publication Publication Date Title
DK1079826T3 (da) Anvendelse af indigoide bisindolderivater til fremstilling af et medikament til inhibering af cyclinafhængige kinaser
FR21C1010I1 (da)
MEP13408A (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
JO2503B1 (en) Benzathiazole derivatives
NO20051647L (no) Pyrazolopyrimidiner som syklinavhengige kinaseinhibitorer
AR022665A1 (es) Compuestos farmaceuticamente activos
MY139336A (en) N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MY137843A (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
UY27592A1 (es) Nuevo uso
HUP0204141A2 (hu) Pirido[2,3-d]pirimidin-2,7-diamin típusú kináz-inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TW200420564A (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
DE69928235D1 (de) Cyclin-abhängige kinase inhibitoren
ATE410426T1 (de) Heterocyclische verbindungen alsccr5-antagonisten
TR200101860T2 (tr) Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
SE9904129D0 (sv) Novel compounds
AU2001235669A1 (en) Use of xanthine derivatives for preparing a medicine for preventing and treatingosteoporosis